藍豐生化(002513.SZ)收到應訴通知書及民事起訴狀
格隆匯2月9日丨藍豐生化(002513.SZ)公佈，原告大秦建設集團有限公司(原告，“大秦建設”)與被告宜君鼎盛傑作醫藥產業開發有限公司(被告1，“鼎盛傑作”)、陝西方舟製藥有限公司(被告2，公司全資子公司，“方舟製藥”)、江蘇藍豐生物化工股份有限公司(被告3，“公司”、“藍豐生化”)建設工程施工合同糾紛一案，陝西省銅川市中級人民法院於2020年1月13日立案。2020年2月9日，公司收到陝西省銅川市中級人民法院送達的《應訴通知書》【(2020)陝02民初9號】及《民事起訴狀》。
原告訴稱：2016年12月9日，原告大秦建設中標方舟製藥新廠區建設工程項目。同年12月20日大秦建設與鼎盛傑作簽訂協議，約定由大秦建設承包鼎盛傑作發包的方舟製藥現代醫藥產業園一期建設項目第一標段工程。合同簽訂後，大秦建設根據約定進行全面施工建設，但鼎盛傑作未按合同約定按時向大秦建設支付工程進度款。大秦建設已完工工程總價為7230.2587萬元，而鼎盛傑作前後支付了4250萬元，剩餘款項一直未支付。方舟製藥作為上述工程項目的業主和實際使用人，應當對鼎盛傑作拖欠的工程款承擔連帶還款責任。方舟製藥是藍豐生化的全資子公司，在方舟製藥興建廠房(即上述工程項目)時，藍豐生化已明確表示由其提供擔保，藍豐生化應當對鼎盛傑作拖欠的工程款承擔連帶還款責任。
訴訟請求：1、請求人民法院依法判令鼎盛傑作向大秦建設支付拖欠的工程款2980.26萬元，以及承擔逾期支付工程款的利息人民幣約163.86萬元。
2、請求人民法院依法判令方舟製藥、藍豐生化對上述款項承擔連帶還款責任。
3、本案全部訴訟費由被告承擔。
公司認為，方舟製藥及公司與原告大秦建設未簽署有關經濟協議，不存在合同關係，亦不應承擔擔保義務。因本案尚未開庭審理，暫時無法預計本次訴訟對公司本期利潤或後期利潤的影響，公司將依照法律法規，維護自身合法權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
